Bropirimine

Bropirimine (U-54461; U-54461S; PNU-54461) is an orally active TLR7 agonist. Bropirimine inhibits RANKL-induced osteoclast differentiation of mouse bone marrow-derived macrophages (BMMs) . Bropirimine exhibits dose-dependent direct inhibitory effects on colony formation of cultured KK-47 and 724 cells. Bropirimine can be used for the study of cancers and bone metabolic disorders such as osteoporosis[1][2][3].

Product Specifications

CAS Number

[56741-95-8]

Product Name Alternative

U-54461; U-54461S; PNU-54461

UNSPSC

12352005

Hazard Statement

H361

Target

Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bropirimine.html

Purity

99.94

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1NC(N)=NC(C2=CC=CC=C2)=C1Br

Molecular Formula

C10H8BrN3O

Molecular Weight

266.10

Precautions

H361

References & Citations

[1]Suzuki H, et al. Bropirimine inhibits osteoclast differentiation through production of interferon-β. Biochem Biophys Res Commun. 2015;467 (1) :146‐151.|[2]Tei Y, et al. In vitro antitumor activity of bropirimine against urinary bladder tumor cells. Anticancer Res. 2002 May-Jun;22 (3) :1667-71.|[3]Fujioka T, et al. Antitumor effects of oral administration of an interferon-inducing pyrimidinone, Bropirimine, on murine renal-cell carcinoma. Cancer Chemother Pharmacol. 1995;36 (1) :7-12.